Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: the United Kingdom Named Patient Programme

Khan, F., Ottensmeier, C., Popat, S., Dua, D., Dorey, N., Ellis, S., Szabo, M., Upadhyay, S., Califano, R., Chan, S., Lee, L., Ali, C.W., Nicolson, M., Bates, A.T., Button, M., Chaudhuri, A., Mulvenna, P., Shaw, H.M. and Danson, S.J. (2014) Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: the United Kingdom Named Patient Programme. European Journal of Cancer, 50 (10), 1717-1721. (doi:10.1016/j.ejca.2014.03.001). (PMID:24726055)

Abstract

INTRODUCTION: Afatinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) who were previously sensitive to erlotinib or gefitinib. This study investigated experience of afatinib under a Named Patient Use (NPU) programme.

PATIENTS AND METHODS: Retrospective data for 63 patients were collected, including demographics, dose, toxicity and clinical efficacy.

RESULTS: Response rate and median PFS were 14.3% and 2.6months, respectively. Diarrhoea and rash were the most common toxicities; 46% of patients required a dose reduction and 41% had a dose delay.

CONCLUSIONS: Efficacy and safety in the NPU programme are consistent with the LUX-Lung 1 trial.

This record has no associated files available for download.

Contributors

Download statistics